and diabetes treatment medication (18,505,015 euro). Highest yearly costs per complication (all cases, all occurrences) were estimated for dialysis I and III (9,162,635 euro), stroke first year costs (4,951,306 euro) and congestive heart failure first year costs (4,879,533 euro). Yearly per one patient, the complication costs were highest for kidney transplantation, followed by dialysis I and III (78,621.25 euro and 36,797.73 Ključne besede: sladkorna bolezen tipa 2, stroški bolezni, javno zdravje, izdatki za zdravje, Slovenija, zapleti
Zaključek: V primerjavi s prej objavljenimi podatki v literaturi so v tej raziskavi objavljeni letni neposredni medicinski stroški primerljivi, čeprav so letni stroški na osebo ocenjeni nižje kot drugje. Prav tako so stroškovne ocene posameznih zapletov sladkorne bolezni primerljive s prej objavljenimi.
Ključne besede: sladkorna bolezen tipa 2, stroški bolezni, javno zdravje, izdatki za zdravje, Slovenija, zapleti
The included diabetes complications were nephropathy, retinopathy, neuropathy, foot ulcer complications, cardiovascular complications, cerebrovascular complications and hypoglycaemia (hypoglycaemia as an adverse effect of anti-hyperglycaemic therapy). The cost also included depression treatment and medical technical devices costs. The costs for primary health care, outpatient specialist care and rehabilitation care were estimated on the feefor-service payments according to The Health Insurance Institute of Slovenia's classification of services, namely "The Green Book", its annual general agreements and the corresponding average healthcare prices for October 2011 (5) (6) (7) (8) . Acute inpatient care costs (from October 2011) were assessed using the Diagnosis Related Group (DRG) payment model, which is in use in Slovenia since 2003 (9, 5) . To calculate the average DRG weight of an acute complication, all DRG codes related to that complication were adjusted to their occurrence rates. The emergency ambulance care costs were evaluated through an expert panel. The service providers are paid by The Health Insurance Institute of Slovenia in flat, meaning that the cost details are not publicly available and consequently an expert opinion was needed. The costs were revalorised to October 2011. Diabetes treatment drug costs and diabetes comedication costs were estimated on the drug prices thatare publicly available by the Agency for Medical Products and Medical Devices of the Republic of Slovenia (October 2011) and The Health Insurance Institute of Slovenia's outpatient drug dispense for the year 2008 database (1) (2) (3) . The latter contains records of all drug dispenses in a particular year, including anonymous patient, health service provider and pharmacy data, anatomical therapeutic classification codes (ATC), drug working codes and expenses, therefore its use in cost studies is highly beneficial. Because of the medication pricing system in Slovenia, the database drug expenses were not revalorised and for simplicity we assumed that they were the same in 2011. The academic research on the database was conducted on behalf of the agreement between the Faculty of Pharmacy Ljubljana and The Health Insurance Institute of Slovenia. Because of anonymous
INTRODUCTION
According to the World Health Organisation, 285 million people are currently suffering from diabetes. Newer projections are predicting that the number of cases will rise to 439 million by2030 (1) . Global costs for the treatment of diabetes in the year 2010 were estimated to 376 billion dollars and according to predictions they will rise to 490 billion dollars in the year 2030 (2) . Consequently, diabetes prevalence in Europe is expected to rise from 10 to 15 million patients in 2006 to 60 million patients in 2025 (3). In Slovenia, the latest known number of patients with type 2 diabetes was 118,750 (also considered in the Slovenian national program for diabetes control), with the incidence of 4,000 to 5,000 new cases yearly (3, 4) . A previously published study showed that in 2006 type 2 diabetes accounted for 36.8 million euro in direct medical healthcare costs in Slovenia (3). The estimated costs represented 2.05% of total planned public healthcare expenditures and were simulated by a decision tree model for 170,000 patients (officially known and unknown cases) that were supposed to be optimally treated, focusing mainly on cardiovascular and cerebrovascular diabetes complications (3, 5) . Therefore, the estimated expenditures were assessed too low. The aim of this study was to revise, update and compare to previously published data healthcare costs of type 2 diabetes in Slovenia with additional consideration of nephropathy, retinopathy, neuropathy, foot ulcer complication costs, depression treatment costs and medical technical devices costs.
METHODS
The study was performed from the healthcare payer perspective. Therefore, the following direct medical costs that are relevant from compulsory and complementary health insurance were included in the analysis: costs for primary health care, outpatient specialist care, acute inpatient care, emergency ambulance care, rehabilitation care and drugs. Estimation was made for 118,750 patients using the bottom-up approach and prevalence based. No group of patients was followed. patient data, privacy protection was assured. The database was not publicly available. Medical technical devices costs were calculated through usage of The Health Insurance Institute of Slovenia's medical technical devices database, its business report for the year 2011 and device consumption literature data (1-3). The overall direct medical healthcare costs were calculated by multiplying the quantities of the complication occurrences with obtained costs. The occurrence rate of an individual diabetes complication was assessed combining the Health Insurance Institute of Slovenia's published data and data published on Medline. The first year occurrence rates were assessed from incidence data, consequently the following year occurrence rates were assessed from prevalence with subtraction of incidence data. Because the overall type 2 diabetes expenses were derived from complication and drug costs that depend on average healthcare prices for the given year, we concluded that the total cost calculation is valid for the year 2011, although type 2 diabetes prevalence data derives from the year 2007 and the DRG incidence rates from 2009 (4, 10) . For verification of obtained cost items and estimating external comparability, we compared our evaluated diabetes complication costs of dialysis, transplantation, amputation, myocardial infarction, stroke, hypoglycaemia and costs of drugs (blood glucose lowering) with previous published studies. The following search phrases (yielded over 10,000 articles) were used: -(economic OR cost OR costs) AND ("renal disease" OR "renal replacement" OR dialysis OR "kidney transplantation") -(economic OR cost OR costs) AND ("lower extremity amputation") -(economic OR cost OR costs) AND (stroke OR infarction) -(economic OR cost OR costs) AND (complications AND diabetes) -(economic OR cost OR costs) AND hypoglycaemia The relevant articles for this publication were selected using a three stage approach. In the first stage, we selected appropriate articles based on title keyword relevance, excluding the majority of obtained search results. In the second stage, the selected articles were then screened through their abstract relevance, resulting in 61 articles remaining. In the last, third stage, we selected articles that clearly described the structure of the costs estimations and were freely available or the abstract contained all needed information and the result was given per patient/per complication/per year (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Table A and B with detailed descriptions of the relevance and validity of the data used and validity of assumptions.
Please refer to supplementary

RESULTS
Yearly type 2 diabetes burden estimation from the payer perspective in Slovenia
The total yearly direct medical costs of type 2 diabetes in Slovenia were estimated to be 99,120,419 euro, with an annual per capita cost of 834.70 euro. The largest cost components were cardiovascular complication costs (21,683,919 euro), diabetes co-medication costs (20,977,269 euro) and diabetes treatment drug costs (18,505,015 euro) (6, 8-11, 1-3, 47 ).The latter were followed by nephropathy costs (13,032,321 euro), which accounted for a significant cost share despite their low yearly complication occurrence count (6, 7, 9, 12, 1-7). Also high were estimated costs for medical technical devices, which totalled 9,717,892 euro yearly (14-16). Cerebrovascular complications further accounted for a 7.10% cost share (7,041,178 euro), foot ulcer complications for a 5.15% share (5,108,738 euro) and neuropathy for a 1.06% cost share (1,054,500 euro) (6, 8-12, 36, 1-5, 53, 54) . The lowest cost components were estimated for depression (712,560 euro), retinopathy (670,694 euro) and hypoglycaemia (616,333 euro) (6, 9, 10, 12, 13, 41, 1-8).
Highest yearly costs per complication (all cases, all occurrences) were assessed for dialysis I (haemodialysis) and III (haemodiafiltration) following years costs (9,162,635 euro), which were followed by stroke first year costs (4,951,306 euro), congestive heart failure first year costs (4,879,533 euro), amputation costs (4,249,724 euro) and peripheral vascular disease following year costs (3,475,348 euro) (6-11, 35, 37, 38, 42, 45-47) . Also significantly high were estimated yearly costs for congestive heart failure in following years (3,273,440 euro) and costs for myocardial infarction in following years (2,877,831 euro) (6, 9, 11, 47) . The detailed complication cost breakdown with corresponding sources is presented in Table 1 and in  supplementary Table A and B.
Yearly costs for a single type 2 diabetes complication occurrence
Among nephropathy, the highest yearly cost for a single complication occurrence was estimated for kidney transplantation, followed by dialysis I and III (78,621.25 euro and 36,797.73 euro) (7, 9, 42 
Comparison of complications and drug costs to previous cost estimation studies
As already pointed out, for verification of obtained cost items and evaluating external comparability, we compared our calculated type 2 diabetes costs with published estimations elsewhere. The findings are written below. The costs for haemodialysis published before in the literature are on average similar to the costs estimated in the present article (36, 797 .73 euro). The estimations ranged from 29,786 euro in Spain (first estimation) to 61,000 euro in France and Germany (18, 19) . The most similar costs to the ones in Slovenia were assessed for the United Kingdom (35,500 euro) and Spain (second estimation, 37,968 euro) (17, 18, 20) . Consequently, we can assume that our estimated cost for dialysis is in general similar to the one published before. We also cannot significantly alter our dialysis cost results, because they mainly consist of publicly announced payer reimbursements.
Regarding the assessment of transplantation costs, our estimation (78,621.25 euro) is higher than those in the Netherlands, France and Belgium (25,000-50,000 euro), Austria (51,000 euro) and Spain (38,313 euro) (18, 21, 20) . Only in France were the costs estimated in 2010 higher (86,000 euro) (22) . The published studies cover the hospitalisation and graft replacement procedure. Our expenditure estimation is based on published healthcare prices, which do not provide a price breakdown, so we cannot examine why our estimations are higher. The expense payer burden comparison was also made for amputation, where our estimated costs (7,884.46 euro) were on average similar to the costs published previously (as in the case of dialysis). The lowest estimation established before was in Singapore (5,188.33 euro) and the highest in Canada (11,553.02 euro) (23, 24) . Most similar was the estimation for Australia, which totalled 9,450 euro (25) . From the obtained comparable costs, we can assume that our amputation costs are assessed correctly. Concerning the myocardial infarction occurrence, our estimated costs (2,813.91 euro only hospitalisation costs) were in terms of a wide-range assessed lower than in similar studies, although still comparable. The before published studies estimated infarction costs (only hospitalisation) to 3,502 euro in France, 3,387 euro in Germany, 3,064 in Italy, 3,870 euro in the Netherlands, 2,300 euro in Poland and 2,488 to 3,284 euro in Ireland (26) (27) (28) . However, with the addition of ambulance and rehabilitation costs, our calculated costs (5,290.66 euro) were more comparable to before published data for France (5,916.45 euro), the Netherlands (5,599.30 euro) and to some extent less comparable to Italian costs (7,450.22 euro) (29) . Nonetheless, we can assume that our estimations were made correctly. With reference to stroke episode costs, which we estimated to 3,794.20 euro (hospitalisation costs), comparison was established for France (4,115 euro), Germany (3,980 euro), Italy (3,601 euro), Poland (3,434 euro), the Netherlands (4,548 euro), Argentina (2,993 euro) and Eastern Europe (2,822) (26, 30, 31) . Significantly higher were published estimations for Belgium (6,188 euro) and Western Europe (9,438 euro) (32, 31) . The Belgian study encompassed costs for stroke and its associated disorders, which is the explanation for a higher payer burden. Regarding the higher Western Europe cost estimations, it has to be considered that the article also included studies with a longer (> 12 months) follow-up. This study also exposed the wide gap in healthcare prices between different geographic regions, as can be seen from low East European stroke costs. 
Study approach commentary
The performed cost study was prevalence based, used the bottom-up approach and considered direct medical costs that are covered by the Slovenian healthcare payer. In comparison to incidence based studies, our approach utilised a lesser amount of data, because there was no need for survival rate and the course of illness progression data. However, the cost calculation could be less accurate, as the prevalence based studies use mainly average case cost data instead of longitudinal illness development data. Because diabetes is related to a significant number of complications, the bottom-up approach is a more valid method to estimate costs. With the usage of the topdown approach, the confounding variables and effect modification could lead to a higher overestimation of costs. With the usage of the bottom-up approach, this overestimation can be avoided.
In the present study, we estimated only direct medical costs, because the study was conducted from the Slovenian healthcare payer perspective. Therefore, a cost estimation from the societal perspective or business perspective was not needed, and the calculation of direct nonmedical or indirect costs could be avoided.
Study limitations
With regard to study limitations, we found no recent public available type 2 diabetes prevalence estimation for Slovenia than that from the year 2007 (used in the Slovenian national program for diabetes control) (4).
Because incorrectly estimated prevalence data could have a significant impact on the total cost calculation, the authors concluded to not predict any prevalence and therefore avoid a possible overestimation. Consequently, the assumption was made that the type 2 diabetes prevalence from 2007 is still valid for 2011. Secondly, the costs had to be calculated from multiple cost data sources. This limitation presented for the research a lesser issue because all expenses could be derived from Slovenian sources excluding foreign data. Also, a limitation was the usage of foreign literature data for the assessment of cardiovascular and cerebrovascular complications prevalence rates among type 2 diabetes patients. Nevertheless, the literature provided complications rates were utilised for the costs calculations with the assumption that they are similar to the ones occurring in Slovenia. In the future, it would be beneficial to have access to Slovenian data.
For the cost calculation of acute complications, we used the DRG payment model. The model does not distinguish between non-diabetes and diabetes patients, therefore our estimated cost could be underestimated because the average DRG weight is calculated from the average population. Also, there is a possibility that DRG codes contain incorrect ICD code records, which is a consequence of coding mistakes in praxis (2) . In regard to hypoglycaemia, only costs for severe hospitalised cases were considered. Non severe cases can be treated by glucose ingestion, and the costs are minor in comparison to the hospitalisation costs. Furthermore, the non-hospitalised severe cases can be treated with glucose solution or glucagon injection by trained non-professionals or by professionals. Because the cost of such treatment is also low and we were unable to determine the proportion by which the treatment was performed, these costs were omitted. Regarding the cost estimation for medical technical devices, we calculated only costs for type 2 diabetes patients on insulins, because type 2 patients on blood glucose lowering drugs are by the health care payer in Slovenia not eligible for most of the devices, except in the case of test strips for optical reading (2) . The latter represent a minor effecton the yearly per patient cost, therefore such estimation is appropriate.
CONCLUSION
We performed a direct medical costs study of type 2 diabetes in Slovenia and estimated the yearly costs to 99,120,419 euro, with annual per patient costs of 834.70 euro in the year 2011. The result represents 4.18% of total planned public healthcare expenditures. The highest cost shares were attributed to cardiovascular complications, diabetes co-medication, diabetes treatment medication, nephropathy complications, medical technical devices and cerebrovascular complications. Consequently, all of them are a subject to be addressed when type 2 diabetes healthcare burden impact reduction is considered. The type 2 diabetes cost estimation study was difficult to conduct for the reason that multiple complications or cost components had to be considered and for every complication reasonable and accurate cost data was needed, together with valid prevalence or incidence information. It was particularly difficult to distinguish between non type 2 diabetes patients and type 2 diabetes patients with regard to incidence and prevalence data. However, with the literature search we could discover the necessary information and reasonably estimate the shares. The latter therefore clearly indicates that the calculated expenses represent merely an estimation that should be carefully considered when discussing diabetes costs.
In the future, it would be beneficial to conduct a micro costing study to obtain more detailed data about the cost structure of diabetes treatment or diabetes complications.
